ORY-1001   Click here for help

GtoPdb Ligand ID: 8390

Synonyms: RG-6016
Compound class: Synthetic organic
Comment: ORY-1001 is a selective and irreversible inhibitor of lysine (K)-specific demethylase 1A (KDM1A, aka LSD1) [2], in clinical development by Oryzon Genomics. Structurally it is a derivative of tranylcypromine. ORY-1001 is claimed in patent WO2010084160 A1 [1]. We provide the structure for the parent compound and the dichloride salt is represented in PubChem CID 71664305.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 38.05
Molecular weight 230.18
XLogP 2.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC1CCC(CC1)NC1CC1c1ccccc1
Isomeric SMILES NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1
InChI InChI=1S/C15H22N2/c16-12-6-8-13(9-7-12)17-15-10-14(15)11-4-2-1-3-5-11/h1-5,12-15,17H,6-10,16H2/t12?,13?,14-,15+/m0/s1
InChI Key ALHBJBCQLJZYON-PFSRBDOWSA-N
No information available.
Summary of Clinical Use Click here for help
ORY-1001 was designated as an 'orphan-medicinal-product' for the treatment of acute myeloid leukemia (AML) by the EMA in 2013. Phase 1 clinical trials are underway in the UK and Spain, evaluating ORY-1001 as a potential treatment for relapsed or refractory acute leukaemia.